They will support early phase development of New Synthetic Molecules particularly newly emerging modalities such as peptides, siRNA, conjugatable payloads for Antibody Drug Conjugates, and small molecules, in both the preclinical- and clinical-development space and collaborate within the global Analytical R&D organization and with R&D cross-functional partners such as Pre-Clinical Safety (PCS), Process Chemistry, Process Engineering, Drug Product Development (DPD), Quality Assurance (QA), and CMC-Regulatory Affairs. This position will focus primarily on transitioning NCEs from Discovery into Development Sciences and the individual will independently serve as an Analytical Research and Development analyst to support a highly cross-functional team, which includes Discovery, Process Chemistry, Quantitative and Translational ADME Sciences (QTAS), Safety Pharmacology, Pre-Clinical Safety (PCS), and Molecular Profiling and Drug Delivery (MPDD).